Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease

Current Medical Research and Opinion

Volumn 28, Issue 4, 2012, Pages 493-501

  Chen, Shih Yin ^a   Siu, Kimberly ^b   Kovacs, Birgit ^b   Stokes, Michael ^a   Rao, Preethi ^a   Sander, Stephen ^b   Boulanger, Luke ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Antidiabetic drugs; Chronic kidney disease; Clinical outcomes; Economic outcomes; Type 2 diabetes

Indexed keywords

ORAL ANTIDIABETIC AGENT;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; ECONOMIC ASPECT; ELECTRONIC MEDICAL RECORD; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REGRESSION ANALYSIS;

ADMINISTRATION, ORAL; AGED; COSTS AND COST ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE;

EID: 84859712926     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.658909     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31: 596-615
3. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl 1):S11-S61
4. U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011
5. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet: General Information and National estimates on Chronic Kidney Diseases in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2010
6. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
7. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49(Suppl 2): S12-S154
8. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-43
9. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and Stratification. Natioal Kidney Foundation; 2002. http://www.kidney.org/professionals/KDOQI/guidelines-ckd/toc.htm
10. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130: 461-70 (Pubitemid 29135798)
11. D'Hoore W, Bouchaert A, Tilquin C. Practical consideration on the use of the Charlson comorbidity index with administrative databases. J Clin Epidemiol 1996;49:1429-33 (Pubitemid 27028932)
12. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29: 891-8
13. Bureau of Labor Statistics. Consumer Price Index. Available from: http://www.bls.gov/cpi/. Accessed 21 January 2011
14. Greene WH. Econometric Analysis, 5th edn. Upper Saddle River, New Jersey: Pearson Education, Inc., 2003
15. Efron B, Tibhirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993
16. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70 (Pubitemid 39422090)
17. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health costs and utilization. JAMA 2001;285:182-9 (Pubitemid 32048520)
18. Menzin J, Langley-Hawthorne C, Friedman M, et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2011;24:51-5